Table 2.
Pt # | Gene | Protein Variant | Variant Class |
Translation al Impact |
1st diagnosis and age |
2nd diagnosis and age |
FDR with Gastric |
SDR with Gastric |
Histology of Gastric Cancer |
Country of Origin |
---|---|---|---|---|---|---|---|---|---|---|
1 | ATM | p.D2569* | P | frameshift | Gastric 66 | 6 | 1 | Adenocarcinoma, Diffuse Type with Signet Rings | U.S.A. | |
| ||||||||||
2 | ATR | p.S1609* | LP | stop gain | Gastric 29 | 1 | 2 | Adenocarcinoma, Intestinal Type | U.S.A. | |
| ||||||||||
3 | BRIP1 | p.L43fs*11 | P | frameshift | Gastric 19 | 0 | 0 | Adenocarcinoma, Intestinal Type | U.S.A. | |
| ||||||||||
4¥ | CDH1 | Exon 1–2 deletion | P | deletion | Gastric 45 | 2 | 1 | Adenocarcinoma, Diffuse Type | U.S.A. | |
| ||||||||||
5¥ | CDH1 | p.Arg335Ter | P | stop gain | Gastric 42 | 2 | 2 | Adenocarcinoma, Diffuse Type with Signet Rings | U.S.A. | |
| ||||||||||
6¥ | CDH1 | p.Arg335Ter | P | stop gain | Gastric 68 | 5 | 0 | Adenocarcinoma, Diffuse Type | U.S.A. | |
| ||||||||||
7¥ | CDH1 | p.Arg335Ter | P | stop gain | Gastric 33 | 2 | 0 | Adenocarcinoma (presumed) | U.S.A. | |
| ||||||||||
8¥ | CDH1 | p.A719Lfs*3 | P | frameshift | Gastric 22 | 1 | 1 | Adenocarcinoma, Diffuse Type with Signet Rings | U.S.A. | |
| ||||||||||
9¥ | CDH1 | c.48+2T>C | LP | Splicing | Gastric 42 | 0 | 3 | Adenocarcinoma, Poorly Differentiated | U.S.A. | |
10 | CTNNA1 | p.R129* | P | stop gain | Gastric 28 | 0 | 0 | Adenocarcinoma, Poorly Differentiated | U.S.A. | |
| ||||||||||
11 | FANCC | p.R548* | P | stop gain | Gastric 50 | 1 | 0 | Adenocarcinoma, Poorly Differentiated | U.S.A. | |
| ||||||||||
12 | FLCN | p.F20fs*35 | P | frameshift | Gastric 17 | 0 | 0 | Adenocarcinoma, Diffuse Type with Signet Rings | U.S.A. | |
| ||||||||||
13¥ | MSH2 | Exon 1–6 deletion | P | deletion | Gastric 30 | Ovarian 45 | 0 | 0 | Adenocarcinoma (presumed) | U.S.A. |
| ||||||||||
14 | SBDS | p.K62* | P | stop gain | Gastric 40 | 0 | 0 | Adenocarcinoma, Diffuse Type | U.S.A. | |
| ||||||||||
15¥ | TP53 | p.R213* | P | stop gain | Gastric 40 | Breast 42 | 0 | 0 | Adenocarcinoma, Diffuse Type with Signet Rings | U.S.A. |
| ||||||||||
16 | TP53 | p.Q317fs*28 | LP | frameshift | Gastric 47 | Sarcoma 48 | 0 | 0 | Gastrointestinal Stromal Tumor | U.S.A. |
OGG1 | p.L22fs*38 | LP | frameshift | |||||||
POLG | p.R1096H | P | missense | |||||||
| ||||||||||
17 | BRCA2 | p.A938fs*21 | P | frameshift | Esophageal 58 | Gastric 58 | 0 | 0 | Adenocarcinoma, Intestinal Type | U.S.A. |
ITGB7 | p.H569fs*116 | PTVUS | frameshift | |||||||
| ||||||||||
18 | GNAS | p.E138* | LP | stop gain | Gastric 30 | Breast 50 | 0 | 1 | Adenocarcinoma (presumed) | Peru |
PARP3 | p.L285fs*52 | PTVUS | frameshift |
Some participants (Pt) had greater than one variant, shown by alternating colors and Pt#.
No variants were seen more than once. Clinically tested (¥). Cancer diagnoses with age diagnosed is provided. Missing histology has been recorded as Adenocarcinoma (presumed).
Protein truncating variants of uncertain significance (PTVUS), pathogenic (P), and likely pathogenic (LP) variants are included. The number of first (FDR) and second degree (SDR) family members with gastric cancer are provided. United States of America (U.S.A.). Two patients with CFTR variants were removed.